Ep203: Sri Kosuri on Small Molecule Correctors of Disease
16.06.2026 | 1 godz. 11 min.
Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many diseases.
Ep202: Becky Pferdehirt on Reimagining Science for the AI Era
02.06.2026 | 1 godz. 8 min.
Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI.
Ep201: Jeremy Levin on Biotech in the Balance
19.05.2026 | 1 godz. 8 min.
Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust."
Ep200: Richard Pops Reflects on a 35-Year Career in Biotech
05.05.2026 | 1 godz. 13 min.
Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.
Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era
21.04.2026 | 1 godz. 10 min.
Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.